Revenue of Rs.11,223 million (US$117.5 million) — up 39.5% YoY and 5.6% QoQ in INR terms (27.5% YoY, 4.4% QoQ in USD), the fifth consecutive quarter of >5% QoQ growth in INR terms.
EBITDA of Rs.1,873 million at 16.7% margin — up 32% YoY, absorbing a ~150 bps impact from the annual wage hike effective in the quarter; productivity gains and favorable exchange rates largely offset the hit.
PAT of Rs.1,123 million (10% margin) — up 10% YoY; PBT was Rs.1,474 million at a 23.8% effective tax rate.
Interest income fell 44% QoQ — from Rs.237 million to Rs.134 million as rising rates toward quarter-end marked down mutual fund NAVs; lower yields impacted PBT by ~90 bps and PAT by ~70 bps QoQ.
Cash and investments of Rs.13,896 million — at end-Q2 FY 2026-2027; net DSOs rose 2 days to 69 days, attributed to seasonal delays in customer confirmations (Europe/US summer) and milestone-based billing on outcome contracts.
TTM revenue per employee of USD 79,600 — up from ~USD 69,000 a year earlier, driven by GenAI-enabled delivery and output/outcome-based pricing.
Broad-Based Growth; One Client Slips Below $25M Tier
107 active clients, 31 more than a year ago — 59 clients contributing $1 million+ annually (vs 54 in Q1 FY 2026-2027) and 30 clients above $10 million (one more QoQ).
Top 5 accounts grew 9.2% QoQ and top 20 ~6.7% QoQ — in INR terms in Q2 FY 2026-2027; management said the largest client relationships are starting to move upwards.
9 deal wins with ACVs of ~$1 million+ — including 3 large deals: 1 at $5 million+ and 2 at $3-5 million; most Q2 FY 2026-2027 wins were output/outcome-based rather than FTE-based (all but one, per CFO).
Largest win: a top-5 customer content-platform migration — to geographies outside the US, expanding the US mandate won in Q1 FY 2026-2027; work commenced in Q3 FY 2026-2027 with ramp-up likely impacting Q4 FY 2026-2027 and beyond.
One customer slipped from the $25 million+ cohort — to slightly below in Q2 FY 2026-2027, attributed to a recent volume variation; the quarter's $5-10 million win is with this client, and management expects re-entry into the cohort within 2-3 quarters (Q3 FY 2026-2027 through Q1 FY 2027-2028). No renegotiation is underway with this client.
Largest customer at 7.8% of revenue, top 10 at 49% — revenue from the largest customer eased as Tectonic engagements ramp gradually despite expanding contracted scope; management expects an upward path as execution catches up.
Mix: enterprise commercial ~71%, enterprise medical 25%, others 4% — geographically North America 74%, Europe 23%, rest of world 3% in Q2 FY 2026-2027.
Integrated AI-Led Content Model; Tectonic Scaling Across Geographies
Tectonic run-rate grew from $1 million to $1.7 million per quarter — in Q2 FY 2026-2027, with contracted run-rate having crossed more than $2 million per quarter looking ahead (period unspecified); ramp-up in the Canada market win remains slow.
Tectonic won Canada with the largest customer in that market — following Germany (end of FY 2025-2026) and Spain (Q1 FY 2026-2027) — three markets in three successive quarters and the first outside Europe; demand remains concentrated in the US/North America, with Spain, Germany and the UK as key expansion geographies.
~$2 million Tectonic investment not measured on standalone ROI — CEO Manish Gupta said its purpose is moving upstream, with ROI measured across the full value chain, where management is "very bullish."
Agentic AOR concepting "cracked" — management claims it is "first in the industry, and nobody's close," after a capability build of 2-3 years; a GenAI concepting pilot (disclosed on the Q4 FY 2025-2026 call) made Indegene primary agency for a client's new molecule launch, with enterprise-level engagement meetings underway.
On Anthropic's announced pharma partnerships for AI-driven drug discovery — CEO Manish Gupta said this is not a threat to Indegene's model; the company has a dedicated partnership team in the US and India and is partnering with Frontier Labs and multiple other tech providers, framing the "last mile" of workflow redesign as "an amazing opportunity."
60%+ of revenue is outcome-aligned — management declined to quantify whether this could reach 80-90% in 5 years, noting a residual FTE layer will remain, mostly exports acting as custodians/orchestrators of AI-enabled workflows.
Tandem + Invisage combined into an audience intelligence platform — beneath Cortex, expanding physician profiles from 1.8 million to over 3.6 million; already powering agentic AOR (synthetic KOL research completed in days vs months for a traditional agency).
Margin Path to 19%+ by Q4 FY27; PBT Tailwinds Ahead
Guidance unchanged: quarterly EBITDA margins of 19%+ by Q4 FY 2026-2027 — underpinned by the wage cycle being in the base, positive progress on the outcome-linked omnichannel contract in H1 FY 2026-2027, and Q2 FY 2026-2027 deal wins with a healthy pipeline into H2 FY 2026-2027.
Productivity and workforce transformation contributed ~85 bps — of margin uplift in Q2 FY 2026-2027, a tailwind management expects to continue; on the ~19% path, CFO Suhas Prabhu declined to give specific forward margin guidance, directing investors to the Q1→Q2 FY 2026-2027 margin walk drivers as indicative.
~75% of two-quarter-ahead forex exposure is hedged — at any given point in time (as of Q2 FY 2026-2027); the CFO expects the favorable exchange rate to support margins but flagged that the exchange rate is "difficult to call."
PBT tailwind of up to 90-95 bps expected from Q3 FY 2026-2027 onward — from lower amortization, higher yields, and a shift toward held-to-maturity instruments, helping PAT margin expand faster than EBITDA margin.
Management expects margin growth in H2 FY 2026-2027 to outpace revenue growth — exiting Q4 FY 2026-2027, with workforce transformation, favorable exchange, and operating leverage adding positively in Q3 FY 2026-2027 and more significantly in Q4 FY 2026-2027, including the anticipated $10 million outcome-based contract uplift.
Funding, M&A and Pipeline Data Cited; BioPharm Completes First Year
Pharma/biotech funding up ~85% YoY to over $69 billion — through August 2026, and biopharma M&A roughly doubled to ~$194 billion; 2026 licensing/partnership deal value already exceeds all of CY2025 (industry data cited by management).
The US regulator has approved 45 novel medicines so far in CY2026 — ahead of the record 2023 pace, with priority vouchers cutting review times for selected medicines from about a year to 1.5-2 months.
Industry pipeline at ~12,700 molecules in development globally — >2.5x the 2015 level, with Phase 2 up almost 18% and ~30% of medicines awaiting approval (highest on record); over $40 billion of industry revenue faces patent expiry over the next decade.
BioPharm completed its first year under Indegene as of October 1, 2026 — transition and seller TSA close-out finished by end-February 2026, ahead of the end-March plan, with no client disruption and strong retention; ~$1.5 million of annual cost synergies realized and reinvested, including expanding BioPharm's go-to-market team from 3 to 9 people.
BioPharm earnout second tranche requires revenue growth in excess of 15% in CY2026 over CY2025 — based on the current trajectory, management expects the payout to be close to the maximum amount (entire amount already provided for in the balance sheet).
INDGN Digital Summit 2026 (September 2026, Philadelphia) — drew 120+ senior pharma leaders with 40% higher pharma participation than the prior year; customer themes: operating models matter more than tools, and physicians increasingly find information via AI tools.
H2 FY27 Expected Stronger; $10M Outcome Deal Peaks in Q4
Management believes FY 2026-2027 should be organically stronger than FY 2025-2026 — and that H2 FY 2026-2027 would be stronger than H1 FY 2026-2027; the CFO stated management is "fairly confident" on H2 FY 2026-2027 given where it sits today.
No quarterly guidance given — responding to Ankur Pant (IIFL) on whether Q3 FY 2026-2027 growth would sustain Q2 momentum, CEO Manish Gupta said the company does not give guidance, especially quarter-on-quarter.
$10 million ACV outcome-based deal (contract started January 2026) — revenue recognition begins post 2.5 quarters of the project going live, with the recognition curve expected to peak in Q4 FY 2026-2027; the peak would also have a "meaningful impact" on margin as the company exits Q4 FY 2026-2027. Any true-up is anticipated in Q4 FY 2026-2027, since it is a full-year outcome threshold with data lock and customer confirmation arriving by February/March.
Commercial expected to outpace medical growth over Q3-Q4 FY 2026-2027 — coming off a relatively strong medical growth base; Q2 FY 2026-2027 deal wins were skewed toward commercial, though two $1 million-plus deals closed in medical, and management remains positive on medical given a good deal pipeline.
Others segment to see more uptick in Q3 FY 2026-2027 — as the relatively large clinical-segment deal announced in Q3 FY 2025-2026, which went live a couple of quarters ago and ramped in August (Q2 FY 2026-2027), becomes fully annualized in Q3 FY 2026-2027.
Two restated goals for the remainder of FY 2026-2027 — delivering organic growth with biggest and newer client relationships moving forward together, and getting quarterly EBITDA margins back into the historical range by Q4 FY 2026-2027; management says these keep the company on track for its FY27 goals while building a foundation for FY28.
On competition from TCS's TCS AD (Advanced Discovery) platform — flagged by Rengavarsini K (Wealthified), management does not see IT companies competing in the deals Indegene competes on (IT players operate mainly on the CIO side, while Indegene sells to CMOs and chief medical officers) and stated IT companies are "not a segment we worry about" at least today; primary competition comes from agencies and CROs.
Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.
Powered by Cofacto — AI research platform for Indian stocks, every claim cited from primary filings